Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections

被引：36
|
作者：
Ferrara, Giovanni [2 ,3 ]
Zumla, Alimuddin [4 ]
Maeurer, Markus [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17182 Stockholm, Sweden
[2] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat CAST, Stockholm, Sweden
[3] Univ Perugia, Sect Resp Dis, S Maria Hosp, Terni, Italy
[4] UCL, Sch Med, Div Infect & Immun, London W1N 8AA, England
来源：
AMERICAN JOURNAL OF MEDICINE | 2012年 / 125卷 / 10期
基金：
英国医学研究理事会;
关键词：
Clinical use; Difficult-to-treat infection; Immune response; Intravenous immunoglobulin; Tuberculosis; RED-CELL APLASIA; BACTERIAL-INFECTIONS; REPLACEMENT THERAPY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; GAMMA AUTOANTIBODY; DENDRITIC CELLS; HIV-INFECTION; LUNG-DISEASE; ANTIBODIES;
D O I：
10.1016/j.amjmed.2012.01.023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Traditionally, intravenous immunoglobulin (IVIg) has been used as replacement therapy for patients with primary or secondary immunoglobulin deficiencies. Increasingly, IVIg is being used (in doses higher than for replacement therapy) in certain bacterial or viral infectious diseases. A variety of modes of action have been attributed to the beneficial effects of IVIg, including its interaction with T-cell function, antigen-presenting cell maturation/presentation, combined with a general "tune down" effect on inflammatory reactions. More often, IVIg is being evaluated in clinical trials for the treatment of refractory and difficult-to-treat chronic infections. The evidence, molecular mechanisms, and rationale for the use of adjunct IVIg therapy in infectious diseases are reviewed, and its potential use in the adjunct treatment of difficult-to-treat drug-resistant tuberculosis discussed. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 1036.e1-1036.e8
引用
收藏
页数：8
相关论文
共 50 条
  • [31] The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
    Taheri, Yasaman
    Jokovic, Natasa
    Vitorovic, Jelena
    Grundmann, Oliver
    Maroyi, Alfred
    Calina, Daniela
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [32] INTRAVENOUS IMMUNOGLOBULIN (IVIG) IS EFFECTIVE AND SAFE IN SEVERE OR REFRACTORY RHEUMATIC DISEASES
    Fonseca, R.
    Goncalves, D.
    Aguiar, F.
    Abelha-Aleixo, J.
    Madureira, P.
    Vieira, R.
    Bernardo, A.
    Bernardes, M.
    Mariz, E.
    Costa, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1109 - 1110
  • [33] THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREPARATIONS IN THE TREATMENT OF CHRONIC ENTEROVIRAL INFECTIONS
    MCKINNEY, RE
    MARKERT, ML
    WILLIAMS, LW
    BUCKLEY, RH
    WILFERT, CM
    [J]. PEDIATRIC RESEARCH, 1986, 20 (04) : A297 - A297
  • [34] Using Intravenous Immunoglobulin (IVIG) to Treat Patients with Primary Immune Deficiency Disease
    Bonagura, Vincent R.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 : S90 - S94
  • [35] Using Intravenous Immunoglobulin (IVIG) to Treat Patients with Primary Immune Deficiency Disease
    Vincent R. Bonagura
    [J]. Journal of Clinical Immunology, 2013, 33 : 90 - 94
  • [36] Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
    Parwinder K. Gill
    Stephen D. Betschel
    [J]. Allergy, Asthma & Clinical Immunology, 14
  • [37] Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
    Gill, Parwinder K.
    Betschel, Stephen D.
    [J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2018, 14
  • [38] INTRAVENOUS IMMUNOGLOBULIN (IVIG) TO PREVENT INFECTIONS IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA (BPD)
    MALIK, S
    GIACOIA, GP
    WEST, K
    MILLER, G
    [J]. PEDIATRIC RESEARCH, 1990, 27 (04) : A273 - A273
  • [39] Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach
    van den Bogaart, Lorena
    Manuel, Oriol
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (05):
  • [40] Olanzapine and fluoxetine in difficult-to-treat depressions
    Dubé, S
    Corya, SA
    Tollefson, GD
    Andersen, SW
    Risser, RC
    Case, M
    Briggs, SD
    Tohen, M
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2004, 78 : S48 - S49
12345